Is Agilent Technologies, Inc. overvalued or undervalued?

As of 17 October 2025, Agilent Technologies, Inc. has moved from a very expensive to a fair valuation grade. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 18.73, and a Price to Book Value of 5.36. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E of 31.17, while DexCom, Inc. shows an even more elevated P/E of 53.65, indicating that Agilent is relatively more attractively priced within its industry.
Despite a fair valuation, Agilent's stock has underperformed against the S&P 500 over the longer term, with a 3-year return of 8.70% compared to the S&P 500's 81.19%. However, it has shown stronger short-term performance, with a 1-month return of 11.99% versus the S&P 500's 0.96%. Overall, Agilent Technologies, Inc. is currently fairly valued, with competitive ratios compared to its peers.